In addition, we found similar results when modeling the secondary cessation outcome (time to relapse post-quit over 60 days). There was a consistent interaction effect between the haplotypes and treatment status (H3 compared to H1: RH=0.54, 95% CI=0.33-0.89, p=0.015; H2 compared to H1: RH=0.60, 95% CI=0.37-0.95, p=0.031; omnibus p-value=0.040 for the overall haplotype effect) (Table S4). Figure S1 illustrates the risk for relapse by haplotypes in the entire sample, and stratified by treatment status. Haplotypes were associated with risk of relapse in the placebo group, but not in the active treatment group. Figure S3 shows the risk for relapse by treatment status, stratified by the three haplotype groups. Active treatment was strongly associated with a decreased risk of relapse in individuals with the H3 haplotype (RH=0.48, 95%CI=0.36-0.64, p=9.7×10−7) and H2 haplotype (RH=0.48, 95%CI=0.37-0.62, p=2.7×10−8). Active treatment had no significant effect in those with the H1 haplotype (RH=0.83, 95%CI=0.56-1.24, p= 0.36).
